ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today enrollment in the ongoing ArtVentive EOS™ Endoluminal Occlusion System, OCCLUDE post-market surveillance study.

The study is dedicated to further advancement of use of the ArtVentive EOS™ embolization device in treating venous and arterial cases where the precise placement and immediate, efficient vessel embolization are paramount.

The first Study case was performed at The University Hospital, Leuven, Belgium, where Dr. Geert Maleux successfully treated a patient with the ArtVentive EOS™ device. Dr. Maleux, Professor in the Department of Radiology stated, "The ArtVentive EOS™ device enhances our ability to treat challenging embolization cases. It offers immediate and complete occlusion. The operator can have confidence that the target vessel is occluded. The ArtVentive EOS™ technology allows for shorter procedure times and potentially reduced radiation exposure for both the physician and patient."

“With new experience and a growing body of evidence, we at ArtVentive are very confident about the progress of the ArtVentive embolization devices in the markets in Europe and looking forward to launching the EOS™ for commercial use in the US,” said Dr. Leon Rudakov, President and CTO of ArtVentive. “We expect to continue developing our extensive pipeline of new coming products which may effect the entire embolization market in a very positive and decisive way.”

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is a medical device company focused on developing, manufacturing and globally marketing a family of devices and deepening its already established intellectual property portfolio.

The ArtVentive EOS™ device is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body's vascular system and organ network.

The ArtVentive EOS™ device serves as a proprietary technology platform for several major clinical areas, including peripheral and neurovascular disorders, women's health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.

More information about ArtVentive can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company's current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company's control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company's ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company's future results to differ materially from any forward-looking statements, see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.